Bioenvision to Present at 25th Annual JPMorgan Healthcare Conference
January 08 2007 - 7:00AM
Business Wire
Bioenvision, Inc. (NasdaqGM:BIVN) announced today that Christopher
B. Wood, M.D., Chairman and Chief Executive Officer of the Company,
will present at the 25th Annual JPMorgan Healthcare Conference on
Thursday, January 11, 2007 at 1:00PM ET. The event is being held at
the Westin St. Francis in San Francisco. A live webcast of the
presentation will be available at: www.events.jpmorgan.com under
�Conference Webcasts.� The webcast will be archived and made
available 24 hours after the live presentation. The webcast link
will remain active through January 25th. About Bioenvision
Bioenvision's primary focus is the acquisition, development,
distribution and marketing of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products
for the treatment of cancer, including: Evoltra�, Modrenal� (for
which Bioenvision has obtained regulatory approval for marketing in
the United Kingdom for the treatment of post-menopausal breast
cancer following relapse to initial hormone therapy), and other
products. Bioenvision is also developing anti-infective
technologies, including the OLIGON� technology; an advanced
biomaterial that has been incorporated into various FDA approved
medical devices and Suvus�, an antimicrobial agent currently in
clinical development for refractory chronic hepatitis C infection.
For more information on Bioenvision please visit our Web site at
www.bioenvision.com. Certain statements contained herein are
"forward-looking" statements (as such term is defined in the
Private Securities Litigation Reform Act of 1995). Because these
statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Oct 2023 to Oct 2024